semaglutide cardiovascular outcomes trial Summary of the main of the SUSTAIN-6 Cardiovascular risk reduction with once-weekly

The medication is typically administered once weekly via injection, making it a convenient option for patients struggling with obesity or overweight conditions

Administered as a weekly injection, it helps patients achieve sustainable weight loss

In the STEP trials, participants lost an average of 15-20% of their body weight over 68 weeks, higher than other weight loss medications

When to Contact Your Healthcare Provider Knowing when to seek medical advice is important

Intravenous catheters were placed in the forearms of the participants for blood collection at d 0.30, 0.50, 1.0, 2.0, 4.0, 6.0, 8.0, 12.0 hours, and 24.0 hours post-drug cocktail administration

Vitamin Deficiency Anemia Do you experience ongoing tiredness and weakness paired with unexpected difficulty breathing